



Review article

Epidemiology of Carbapenem Resistant *Klebsiella pneumoniae* Infections in Mediterranean Countries

Corrado Girmenia, Alessandra Serrao and Martina Canichella

Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

Competing interests: The authors have declared that no competing interests exist.

Abstract. Infections by Carbapenem-Resistant Enterobacteriaceae (CRE), in particular, carbapenem-resistant *Klebsiella pneumoniae* (CRKp), are a significant public health challenge worldwide. Resistance to carbapenems in enterobacteriaceae is linked to different mechanisms, including the production of the various types of enzymes like KPC, VIM, IMP, NDM, and OXA-48. Despite several attempts to control the spread of these infections at the local and national level, the epidemiological situation for CRKp had worsened in the last years in the Mediterranean area. The rate and types of CRKp isolates greatly differ in the various Mediterranean countries. KPC-producing *K. pneumoniae* is diffused particularly in the European countries bordering the Mediterranean Sea and is endemic in Greece and Italy. On the contrary, OXA-48-producing *K. pneumoniae* is endemic in Turkey and Malta and diffused at inter-regional level particularly in some North African and Middle East countries. The spread of these multiresistant pathogens in the world and the Mediterranean countries has been related to various epidemiological factors including the international transfer of patients coming from endemic areas.

Citation: Girmenia C., Serrao A., Canichella M. Epidemiology of carbapenem resistant *Klebsiella pneumoniae* infections in mediterranean countries. *Mediterr J Hematol Infect Dis* 2016, 8(1): e2016032, DOI: <http://dx.doi.org/10.4084/MJHID.2016.032>

Published: July 1, 2016

Received: May 18, 2016

Accepted: May 25, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by-nc/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Corrado Girmenia. Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa, Azienda Policlinico Umberto I, Sapienza University of Rome. Via Benevento 6, 00161 Roma, Italy. Fax: 0039-06-44241984. E-mail: girmenia@bce.uniroma1.it

Introduction. Infections by Carbapenem-Resistant Enterobacteriaceae (CRE), in particular carbapenem-resistant *Klebsiella pneumoniae* (CRKp), are a significant public health challenge worldwide.¹⁻⁴ These pathogens are characterized by multiantibiotic resistance which involves penicillins, all cephalosporins, monobactams, carbapenems, and even β -lactamase inhibitors. They are generally only susceptible to a few antibiotics, and there is high mortality among patients with bloodstream infections caused by these organisms. Many CRKp isolates remain susceptible to colistin, tigecycline, and one or more aminoglycoside, but some are resistant even

to these drugs.^{5,6} Moreover, only a few drugs are in development against CRE.⁷ The prognosis of infections by CRKp is particularly poor in high risk immunocompromised populations as intensive care unit (ICU), solid organ transplant (SOT), hematological malignancies (HEM) and stem cell transplant (SCT) patients.⁸⁻¹⁵

Resistance to carbapenems in enterobacteriaceae is linked to different mechanisms, in particular the production of strong carbapenemases, but also of beta-lactamases that possess weak carbapenemase activity when combined with decreased permeability due to porin loss or alteration. Strong carbapenemases

that are responsible for nonsusceptibility to carbapenems, without additional permeability defects, belong to Ambler molecular class A, B, or D. These enzymes are carried either on chromosome or acquired via plasmids.^{16,17}

K. pneumoniae carbapenemase (KPC) enzymes are currently the most clinically significant enzymes among the class A carbapenemases. KPC producing *K. pneumoniae* had the widest dissemination in the last few years being diffused with important regional, interregional and endemic spread in several countries. To date, more than 20 different KPC variants have been described, even though KPC-2 and -3 remain the most commonly identified variants.¹⁸ The class B beta-lactamases or metallo-beta-lactamases (MBLs) have also been identified in various enterobacterial species, including *K. pneumoniae*.¹⁹ They are mainly New Delhi metallo-beta-lactamase (NDM-1), Verona integron-encoded metallo-beta-lactamase (VIM), and Imipenemase (IMP) type enzymes, with the first group being the most commonly identified worldwide. Carbapenem-hydrolysing oxacillinase-48 (OXA-48) is the most frequently reported class D beta-lactamase and microorganisms producing


this enzyme have almost reached the same spread of KPC-producing *K. pneumoniae*.^{17,19,20}

In 2012, the European Centre for Disease Prevention and Control (ECDC) launched the 'European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE)' project to gain insights into the occurrence and epidemiology of CRE and to increase the awareness of the spread of CRE, in Europe.²¹ The epidemiological situation for CRKp had worsened since 2010 and CRKp continued to spread in European hospitals, particularly in the Mediterranean area.

The aim of this review is to describe the recent epidemiological data on the diffusion of CRKp infections in Mediterranean countries.

Epidemiology of CRKp in Mediterranean countries. The epidemiology of the various types of CRKp is characterized by a distribution which does not necessarily overlap in the different countries (**Figure 1**). It is well defined in Europe and Israel where several national and multinational epidemiological surveys have been performed in the last years, on the contrary, the data from North African and Middle East regions, other than Israel, are less accurate.²²

Figure 1. Current epidemiological stages of carbapenem-resistant *Klebsiella pneumoniae* by type of carbapenemase in the Mediterranean countries



Class A KPC type producing K. pneumoniae: KPC was initially reported from *K. pneumoniae* strains isolated in the United States in the late 1990s. KPC producing *K. pneumoniae* has since spread across the United States and the overall prevalence of carbapenem resistance among *Klebsiella* spp. isolates causing hospital-acquired infections in U.S. hospitals was approximately 12% between 2009 and 2010.²³⁻²⁹ KPC-producing *K. pneumoniae* has since spread worldwide. The first country besides the United States that experienced a nationwide outbreak was Israel in late 2005 where the pathogen rapidly became endemic.^{30,31} It was the first outbreak of KPC-producing *K. pneumoniae* in the Mediterranean area, presumably coming from U.S. Hospital-level interventions were implemented but were unable to contain its spread, therefore in 2007 the Israeli Ministry of Health launched a nationwide intervention, which in few months was able to contain the outbreak nationally, with a 79% relative reduction in the incidence compared with its peak the previous year. In Israel KPC-positive *K. pneumoniae* was declared as an endemic phenomenon until 2010, while, thanks to the nationwide infection-control intervention, since 2011 the epidemiological scale downgraded to inter-regional spread.³²

Since the Israeli epidemic, several sporadic cases and outbreaks of KPC type *K. pneumoniae* isolates have been reported in many European countries. In 2007 two cases of KPC-2 positive *K. pneumoniae* infection were diagnosed in France and Sweden, respectively, but both cases were documented in patients transferred from Greece.^{33,34} In the same year an outbreak of KPC-2-positive *K. pneumoniae* was reported from a tertiary hospital in Crete and within 2 years of these reports, the multiresistant pathogen disseminated into all Greek tertiary-care hospitals, not only in Intensive Care Units, but also in medical and surgical wards.³⁵⁻⁴¹ According to the data of the European Antimicrobial Resistance Surveillance Network (EARS-Net) of the European Centre for Disease Prevention and Control (ECDC) the epidemiology of KPC-positive *K. pneumoniae* in Greece was considered at an endemic stage since 2010, and since 2011 the rate of resistance to carbapenems (mainly due to KPC production) was constantly over 60% in invasive *K. pneumoniae* isolates.⁴²

In Italy, the first KPC-positive *K. pneumoniae* strains were isolated in 2008 from an inpatient with a complicated intra-abdominal infection in Florence and in 2009 from two patients admitted to a teaching hospital in Rome.^{43,44} Since then several cases and outbreaks by KPC-2 and KPC-3 *K. pneumoniae* strains were reported as a consequence of a rapid dissemination in almost all hospitals in the north, middle and south regions of the country.^{8,9,13,14,45-51} KPC-positive *K. pneumoniae* have spread rapidly and extensively in Italy, with a sharp increase reported by the EARS-Net surveillance system for bacteraemia isolates, from 1–2% carbapenem resistance in 2006–09 to 26.7% in 2011 and 32.9% in 2014. Since 2013, in Italy the epidemiology of KPC-positive *K. pneumoniae* was declared at an endemic stage.⁴²

The first two KPC positive *K. pneumoniae* clinical isolates (one KPC-2 and one KPC-3) in France were found in 2005.^{52,53} They were recovered from two patients with a recent hospital admission in New York City (USA). A further case was described two years later from a patient transferred from a Greek hospital (see above).³³ Subsequently, other nosocomial clusters have been reported, generally related to patients transferred from other European endemic areas.^{54,55}

In 2012, a national reference centre was established to examine all carbapenem-resistant Enterobacteriaceae in France. Throughout 7 months, out of 160 carbapenemase-positive Enterobacteriaceae identified, 19 (11.9%) KPC-producing *K. pneumoniae* cases were documented.¹ Five of these 19 cases were linked to recent stays in Israel, Italy, Kuwait, and China, none was community acquired. According to the EARS-Net data, in 2014 less than 1% of the invasive *K. pneumoniae* isolates in France were resistant to carbapenems and sporadic hospital outbreaks with no autochthonous inter-institutional transmission have been reported.^{42,56}

The first eight cases of KPC-3-positive *K. pneumoniae* colonizations reported in Spain have been documented in 2009.⁵⁷ These patients were in five different wards in a hospital in Madrid, and none had recently travelled to KPC-endemic countries. Since then, sporadic KPC-positive isolates have been identified in the same hospital and in other hospitals in Valencia. A slight increase of KPC-positive *K. pneumoniae* invasive isolates was observed in the following years in

Spain as documented by the EARS-Net surveillance (from 0.3% in 2011 to 2,3% in 2014). In a multicentre prospective epidemiological study carried out in 83 Spanish hospitals from February to May 2013, out of 374 *K. pneumoniae* isolates 282 (74.4%) were carbapenemase producers but in only 3 (0.1%) cases the carbapenem resistance was related to KPC production.^{58,59} In the period 2014-2015, KPC-positive *K. pneumoniae* was reported at regional stage almost exclusively in the territory of Madrid and Valencia.⁵⁶

To date, only sporadic epidemiological data on KPC-positive *K. pneumoniae* isolates have been reported in other European countries bordering the Mediterranean. Forty-eight KPC-2 producing *K. pneumoniae* isolates, collected during a period from February 2011 to August 2013, were recorded in 9 of 40 centers in Croatia, limited to the northwest region of the country.^{60,61} According to the EARS-Net data, in 2014 0.9% of the invasive *K. pneumoniae* isolates in Croatia and Slovenia were resistant to carbapenems.⁴²

A KPC-3 positive *K. pneumoniae* strain was isolated in Albania in 2014 in an ICU patient with no history of recent travel to endemic areas.⁶² According to the EuSCAPE data no case of KPC-positive *K. pneumoniae* has been reported in 2014-2015 from Montenegro, Malta and Turkey.

With regard to North African and the Middle East regions (excluding Israel), in most of the countries, there is no description or only single cases of KPC producers *K. pneumoniae* isolates.²² A case of KPC-3-producing *K. pneumoniae* meningitis in a 6-month-old child has been reported in Algeria.⁶³ Three studies from tertiary care hospitals in Egypt showed a high prevalence of KPC related carbapenem non-susceptible *K. pneumoniae* (70% in one study) isolates suggesting an underestimated epidemiological phenomenon in that country.⁶⁴⁻⁶⁶

Class B MBLs type producing *K. pneumoniae*: Class B MBLs are mostly of the VIM and IMP types and, more recently, of NDM-1 type.⁶⁷ IMP-type beta-lactamases were the first acquired MBLs to be identified. They have been detected in a series of clinically relevant Gram-negative bacilli including *K. pneumoniae* but with a much lower frequency compared all other carbapenemases. IMP producing *K. pneumoniae*, which is dominant in the Asian continent and Australia, has been only

sporadically detected in Europe and the Mediterranean area.²²

The VIM type MBL is the most commonly found class B carbapenemase which has been identified in all continents.^{19,68} Italy was the first Mediterranean country to report acquired MBLs, with sporadic isolates of VIM-4-producing *K. pneumoniae*.⁶⁹ Since then, single or sporadic hospital outbreaks caused by VIM-1 like enzymes were described from various regions in this country.^{70,71} VIM producing *K. pneumoniae* have not undergone wide dissemination in the other Mediterranean countries, with the exception of Greece where several cases and outbreaks have been reported in the last years.^{67,72} Finally, single reports and local outbreaks of VIM- type producers have been reported in other countries of the Mediterranean area, such as France,⁷³ Spain,⁵⁸ Morocco,⁷⁴ Egypt,⁷⁵ Algeria,⁷⁶ and Tunisia.⁷⁷

The NDM-1 enzyme is a more recently reported class B carbapenemase identified mostly in *E.coli* and *K. pneumoniae* and to a lesser extent in other enterobacteriaceae. NDM-1 producers have been reported in the environment and in the community. It arose from India in 2008 and spread rapidly over Indian subcontinent in the following few years and international travel has a significant impact on its rapid worldwide spread.^{19,78,79} The European epidemiology for CRE changed between 2013 and 2015 for NDM-producing Enterobacteriaceae with several countries reporting regional or inter-regional spread but with no endemic situation. Single or sporadic hospital outbreaks caused by NDM-1 producing *K. pneumoniae* strains were reported from many countries in the Mediterranean area: France,⁸⁰ Italy,⁸¹ Spain,^{82,83} Morocco⁸⁴ Tunisia in a patient transferred from Libya,⁸⁵ and Egypt.⁸⁶ In these countries the dissemination of NDM-producing CRE, including *K. pneumoniae*, was still limited and cases were mostly acquired abroad. Finally, an emergence of autochthonous and imported NDM-1 producing *K. pneumoniae* was reported in Turkey, especially in hospitals from cities close to the Syrian border, and in Greece.⁸⁷⁻⁹⁰ Sporadic cases or single hospital outbreaks by NDM-1 positive *K. pneumoniae* have been observed in Lebanon (imported from Iraq), Israel and other Middle East Mediterranean countries.⁹¹⁻⁹³

Class D OXA-48 type producing *K. pneumoniae*: Class D beta-lactamases, also named OXAs for

oxacillinases, have more than 440 known variants with 232 of them showing carbapenemase activity. OXA-48 represents the main enzyme isolated around the world.¹⁷ It was initially identified in *K. pneumoniae* in a strain from Istanbul, Turkey in 2001.⁹⁴ The OXA-48-positive *K. pneumoniae* strains rapidly diffused in Turkey with hospital outbreaks in the main cities of the country.⁹⁵ The epidemic was under controlled and in 2015 OXA-48 *K. pneumoniae* was considered endemic in Turkey.⁵⁶

Identification of this novel and powerful resistance determinant outside of Turkey indicated that spread was larger than expected. OXA-48 producing isolates disseminated to the Middle East, North Africa and Europe and several nosocomial outbreaks were reported from many Mediterranean countries including France, Spain, Lebanon, Israel, Tunisia and Morocco.⁹⁷⁻¹⁰⁸ Several cases of OXA-48 *K. pneumoniae* infections in Libyan refugees transferred to hospitals of European countries have been reported, suggesting that the epidemiology of such multiresistant microorganisms in Libya, and probably in other north African countries, is underestimated.¹⁰⁹⁻¹¹³ Dramatic epidemiological findings occurred in Malta where dissemination of OXA-48-producing Enterobacteriaceae had changed the country's epidemiological level from rare sporadic occurrence before 2010 to an endemic situation by 2013.^{42,56} Presumably, the influx of injured Libyan war victims to the country's only tertiary care hospital in 2011 contributed to the first outbreak and spread of OXA-48-producing Enterobacteriaceae in the country. Despite initial control of the outbreak, the situation rapidly became endemic in this hospital

and OXA-48-producing *K. pneumoniae* and other enterobacteria spread to other health and residential care entities on the Maltese islands. EARS-Net data for Malta showed an increase in the percentage of invasive OXA-48-producing *K. pneumoniae* in Malta, from 3.8% in 2011, to 5.8% in 2013 and 9.9% in 2014.⁴²

In summary, in 2014-2015 the epidemiological stage for the spread of OXA-48 producing *K. pneumoniae* in the Mediterranean area was: endemic level in Turkey and Malta, inter-regional diffusion in France, Spain, Lebanon, Tunisia, Morocco and Libya, regional diffusion in Italy and Croatia, single or sporadic hospital outbreaks in Israel, Slovenia, Albania, single cases or never reported in Greece, Albania, Montenegro, Syria, Egypt and Algeria.

Conclusions. Despite several attempts to control the spread of CRKp at the local and national level, the epidemiological situation for these multiresistant pathogens had worsened in the last years in the Mediterranean area. The rate and types of CRKp isolates greatly differ in the various countries being the diffusion of these multiresistant pathogens related to various geographic and epidemiological factors including the international transfer of patients coming from endemic areas.

The political and economic relationship and the increasing phenomenon of migration in the Mediterranean basin should lead to a continuous epidemiological survey of multiresistant bacteria in order to define and plan appropriate infection-control intervention at national and international level.

References:

1. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet Infect Dis.* 2013;13:785-96. [http://dx.doi.org/10.1016/S1473-3099\(13\)70190-7](http://dx.doi.org/10.1016/S1473-3099(13)70190-7)
2. Tzouveleakis LS, Markogiannakis A, Psychogiou M, et al. Carbapenemases in *Klebsiella pneumoniae* and other Enterobacteriaceae: an evolving crisis of global dimensions. *Clin Microbiol Rev.* 2012 ;25:682-707. <http://dx.doi.org/10.1128/CMR.05035-11> PMID:23034326 PMID:PMC3485753
3. Cantón R, Akóva M, Carmeli Y, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. *Clin Microbiol Infect.* 2012 ;18:413-31. <http://dx.doi.org/10.1111/j.1469-0691.2012.03821.x> PMID:22507109
4. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers in Enterobacteriaceae worldwide. *Clin Microbiol Infect* 2014;20:821-30 <http://dx.doi.org/10.1111/1469-0691.12719> PMID:24930781
5. van Duin D, Doi Y. Outbreak of Colistin-Resistant, Carbapenemase-Producing *Klebsiella pneumoniae*: Are We at the End of the Road? *J Clin Microbiol.* 2015;53:3116-7. <http://dx.doi.org/10.1128/JCM.01399-15> PMID:26202122 PMID:PMC4572557
6. Monaco M, Giani T, Raffone M, et al. Colistin resistance superimposed to endemic carbapenem-resistant *Klebsiella pneumoniae*: a rapidly evolving problem in Italy, November 2013 to April 2014. *Euro Surveill.* 2014;19(42). <http://dx.doi.org/10.2807/1560-7917.ES2014.19.42.20939> PMID:25358041
7. Syue LS, Chen YH, Ko WC, Hsueh PR. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance. *Int J Antimicrob Agents.* 2016 ;47:250-8. <http://dx.doi.org/10.1016/j.ijantimicag.2015.12.021> PMID:27005457
8. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, et al. Infection with *Klebsiella pneumoniae* carbapenemase (KPC)-

- producing *K. pneumoniae* in solid organ transplantation. *Transpl Infect Dis.* 2012 ;14:198-205. <http://dx.doi.org/10.1111/j.1399-3062.2011.00688.x> PMID:22093103
9. Taglietti F, Di Bella S, Galati V, et al. Carbapenemase-producing *Klebsiella pneumoniae*-related mortality among solid organ-transplanted patients: do we know enough? *Transpl Infect Dis.* 2013;15:E164-5. <http://dx.doi.org/10.1111/tid.12085> PMID:23601113
 10. Kalpoe JS, Sonnenberg E, Factor SH, et al. Mortality associated with carbapenem-resistant *Klebsiella pneumoniae* infections in liver transplant recipients. *Liver Transpl.* 2012 ;18:468-74. <http://dx.doi.org/10.1002/lt.23374> PMID:22467548
 11. Clancy CJ, Chen L, Shields RK, et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant *Klebsiella pneumoniae* in transplant recipients. *Am J Transplant.* 2013;13:2619-33. <http://dx.doi.org/10.1111/ajt.12424> PMID:24011185 PMID:PMC3955300
 12. Satlin MJ, Jenkins SG, Walsh TJ. The Global Challenge of Carbapenem-Resistant Enterobacteriaceae in Transplant Recipients and Patients With Hematologic Malignancies. *Clin Infect Dis.* 2014 ;58:1274-83 <http://dx.doi.org/10.1093/cid/ciu052> PMID:24463280 PMID:PMC4038783
 13. Pagano L, Caira M, Treccarichi EM, et al. Carbapenemase-producing *Klebsiella pneumoniae* and hematologic malignancies. *Emerg Infect Dis.* 2014;20:1235-6. <http://dx.doi.org/10.3201/eid2007.130094> PMID:24960464 PMID:PMC4073839
 14. Girmenia C, Rossolini GM, Piciocchi A, et al. Infections by carbapenem-resistant *Klebsiella pneumoniae* in stem cell transplant recipients: a nationwide retrospective survey from Italy. *Bone Marrow Transplant.* 2015;50:282-8 <http://dx.doi.org/10.1038/bmt.2014.231> PMID:25310302
 15. Girmenia C, Viscoli C, Piciocchi A, et al. Management of carbapenem resistant *Klebsiella pneumoniae* infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. *Haematologica.* 2015;100:e373-6. <http://dx.doi.org/10.3324/haematol.2015.125484> PMID:25862702 PMID:PMC4800687
 16. Nordmann P. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge. *Med Mal Infect.* 2014;44:51-6. <http://dx.doi.org/10.1016/j.medmal.2013.11.007> PMID:24360201
 17. Pitout JD, Nordmann P, Poirel L. Carbapenemase-Producing *Klebsiella pneumoniae*, a Key Pathogen Set for Global Nosocomial Dominance. *Antimicrob Agents Chemother.* 2015;59:5873-84. <http://dx.doi.org/10.1128/AAC.01019-15> PMID:26169401 PMID:PMC4576115
 18. Walther-Rasmussen J, Hoiby N. Class A carbapenemases. *J Antimicrob Chemother* 2007;60:470-482. <http://dx.doi.org/10.1093/jac/dkm226> PMID:17595289
 19. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase producing Enterobacteriaceae. *Emerg Infect Dis* 2011, 17:1791-1798 <http://dx.doi.org/10.3201/eid1710.110655> PMID:22000347 PMID:PMC3310682
 20. Jean SS, Lee WS, Lam C, Hsu CW, Chen RJ, Hsueh PR. Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options. *Future Microbiol.* 2015;10:407-25. <http://dx.doi.org/10.2217/fmb.14.135> PMID:25812463
 21. Glasner C, Albiger B, Buist G, et al. European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. *Euro Surveill.* 2013;18(28). <http://dx.doi.org/10.2807/1560-7917.ES2013.18.28.20525> PMID:23870096
 22. Djahmi N, Dunyach-Remy C, Pantel A, Dekhil M, Sotto A, Lavigne JP. Epidemiology of carbapenemase-producing Enterobacteriaceae and *Acinetobacter baumannii* in Mediterranean countries. *Biomed Res Int.* 2014;2014:305784. <http://dx.doi.org/10.1155/2014/305784> PMID:24955354 PMID:PMC4052623
 23. Rasmussen BA, Bush K. Carbapenem-hydrolyzing β -lactamases. *Antimicrob Agents Chemother.* 1997;41:223-232. PMID:9021171 PMID:PMC163693
 24. Martínez-Martínez L, Pascual A, Hernández-Allés S, et al. Roles of β -lactamases and porins in activities of carbapenems and cephalosporins against *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 1999; 43:1669-1673. PMID:10390220 PMID:PMC89341
 25. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing β -lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 2001; 45:1151-1161. <http://dx.doi.org/10.1128/AAC.45.4.1151-1161.2001> PMID:11257029 PMID:PMC90438
 26. Bradford PA, Bratu S, Urban C, et al. Emergence of carbapenem-resistant *Klebsiella* species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β -lactamases in New York City. *Clin Infect Dis.* 2004; 39:55-60. <http://dx.doi.org/10.1086/421495> PMID:15206053
 27. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant *Klebsiella pneumoniae* in New York City: a new threat to our antibiotic armamentarium. *Arch Intern Med.* 2005; 165:1430-1435. <http://dx.doi.org/10.1001/archinte.165.12.1430> PMID:15983294
 28. Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* isolates in the United States: clonal expansion of multilocus sequence type 258. *Antimicrob Agents Chemother.* 2009; 53:3365-3370. <http://dx.doi.org/10.1128/AAC.00126-09> PMID:19506063 PMID:PMC2715580
 29. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. *Clin Infect Dis.* 2011; 53:60-67. <http://dx.doi.org/10.1093/cid/cir202> PMID:21653305
 30. Samra Z, Ofir O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. Outbreak of carbapenem-resistant *Klebsiella pneumoniae* producing KPC-3 in a tertiary medical centre in Israel, *International Journal of Antimicrobial Agents*, 2007;30:525-529. <http://dx.doi.org/10.1016/j.ijantimicag.2007.07.024> PMID:17931835
 31. Kitchel, Rasheed JK, J Patel JB et al., "Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* isolates in the United States: clonal expansion of multilocus sequence type 258," *Antimicrobial Agents and Chemotherapy*, 2009;53:3365-3370.
 32. Schwaber MJ, Lev B, Israeli A, et al. Containment of a country-wide outbreak of carbapenem-resistant *Klebsiella pneumoniae* in Israeli hospitals via a nationally implemented intervention. *Clin Infect Dis.* 2011;52:848-55 <http://dx.doi.org/10.1093/cid/cir025> PMID:21317398
 33. Cuzon G, Naas T, Demachy MC, Nordmann P. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in *Klebsiella pneumoniae* isolate from Greece. *Antimicrob Agents Chemother.* 2008; 52:796-97 <http://dx.doi.org/10.1128/AAC.01180-07> PMID:18056283 PMID:PMC2224780
 34. Tegmark WK, Haeggman S, Gezelius L, et al. Identification of *Klebsiella pneumoniae* carbapenemase in Sweden. *Euro Surveill.* 2007; 12:E071220. <http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-europe-2014.pdf>
 35. Maltzou HC, Giakkoupi P, Maragos A, et al. Outbreak of infections due to KPC-2-producing *Klebsiella pneumoniae* in a hospital in Crete (Greece). *J Infect.* 2009; 58:213-19. <http://dx.doi.org/10.1016/j.jinf.2009.01.010> PMID:19246099
 36. Pourmaras S, Protonotariou E, Voulgari E, et al. Clonal spread of KPC-2 carbapenemase-producing *Klebsiella pneumoniae* strains in Greece. *J Antimicrob Chemother.* 2009; 64:348-52. <http://dx.doi.org/10.1093/jac/dkp207> PMID:19525514
 37. Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to beta-lactamase *Klebsiella pneumoniae* carbapenemase 2-producing *K pneumoniae* in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. *Clin Infect Dis.* 2010; 50:364-73. <http://dx.doi.org/10.1086/649865> PMID:20041768
 38. Kontopoulou K, Protonotariou E, Vasilakos K, et al. Hospital outbreak caused by *Klebsiella pneumoniae* producing KPC-2 beta-lactamase resistant to colistin. *J Hosp Infect.* 2010; 76:70-73. <http://dx.doi.org/10.1016/j.jhin.2010.03.021> PMID:20705205
 - 39.
 40. Zarkotou O, Pourmaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing *Klebsiella pneumoniae* and impact of appropriate antimicrobial treatment. *Clin Microbiol Infect.* 2011; 17:1798-803. <http://dx.doi.org/10.1111/j.1469-0691.2011.03514.x> PMID:21595793
 41. Bathoorn E, Tsioutis C, da Silva Voorham JM, et al. Emergence of

- pan-resistance in KPC-2 carbapenemase-producing *Klebsiella pneumoniae* in Crete, Greece: a close call. *J Antimicrob Chemother.* 2016;71:1207-12. <http://dx.doi.org/10.1093/jac/dkv467> PMID:26817488
42. Spyropoulou A, Papadimitriou-Olivgeris M, Bartzavali C, et al. A ten-year surveillance study of carbapenemase-producing *Klebsiella pneumoniae* in a tertiary care Greek university hospital: predominance of KPC- over VIM- or NDM-producing isolates. *J Med Microbiol.* 2016;65:240-6. <http://dx.doi.org/10.1099/jmm.0.000217> PMID:26698320
 43. Giani T, D'Andrea MM, Pecile P, et al. Emergence in Italy of *Klebsiella pneumoniae* sequence type 258 producing KPC-3 carbapenemase. *J Clin Microbiol.* 2009; 47:3793-94. <http://dx.doi.org/10.1128/JCM.01773-09> PMID:19759220 PMCid:PMC2772625
 44. Fontana C, Favaro M, Sarmati L, et al. Emergence of KPC-producing *Klebsiella pneumoniae* in Italy. *BMC Res Notes.* 2010; 3:40. <http://dx.doi.org/10.1186/1756-0500-3-40> PMID:20178590 PMCid:PMC2844393
 45. Giani T, Pini B, Arena F, et al. Epidemic diffusion of KPC carbapenemase-producing *Klebsiella pneumoniae* in Italy: results of the first countrywide survey, 15 May to 30 June 2011. *Euro Surveill.* 2013;18 (22). PMID:23787077
 46. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: importance of combination therapy. *Clin Infect Dis.* 2012; 55:943-50. <http://dx.doi.org/10.1093/cid/cis588> PMID:22752516
 47. Giannella M, Treccarichi EM, De Rosa FG, et al. Risk factors for carbapenem-resistant *Klebsiella pneumoniae* bloodstream infection among rectal carriers: a prospective observational multicentre study. *Clin Microbiol Infect.* 2014;20: 1357-62 <http://dx.doi.org/10.1111/1469-0691.12747> PMID:24980276
 48. Giacobbe DR, Del Bono V, Treccarichi EM, et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing *Klebsiella pneumoniae*: results from a multicenter case-control study. *Clin Microbiol Infect.* 2015;21:1106.e1-8. <http://dx.doi.org/10.1016/j.cmi.2015.08.001> PMID:26278669
 49. Monaco M, Giani T, Raffone M, Arena F, Garcia-Fernandez A, Pollini S; Network EuSCAPE-Italy, Grundmann H, Pantosti A, Rossolini GM. Colistin resistance superimposed to endemic carbapenem-resistant *Klebsiella pneumoniae*: a rapidly evolving problem in Italy, November 2013 to April 2014. *Euro Surveill.* 2014;19(42). <http://dx.doi.org/10.2807/1560-7917.ES2014.19.42.20939> PMID:25358041
 50. Aschbacher R, Giani T, Corda D, et al. Carbapenemase-producing Enterobacteriaceae during 2011-12 in the Bolzano area (Northern Italy): increasing diversity in a low-endemicity setting. *Diagn Microbiol Infect Dis.* 2013;77:354-6. <http://dx.doi.org/10.1016/j.diagmicrobio.2013.08.029> PMID:24125922
 51. Tumbarello M, Treccarichi EM, De Rosa FG, et al. Infections caused by KPC-producing *Klebsiella pneumoniae*: differences in therapy and mortality in a multicentre study. *J Antimicrob Chemother.* 2015;70:2133-43. <http://dx.doi.org/10.1093/jac/dkv200>
 52. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a *Klebsiella pneumoniae* isolate from France. *Antimicrob Agents Chemother.* 2005; 49:4423-24. <http://dx.doi.org/10.1128/AAC.49.10.4423-4424.2005> PMID:16189140 PMCid:PMC1251528
 53. Dortet L, Radu I, Gautier V, Blot F, Chachaty E, Arlet G. Intercontinental travels of patients and dissemination of plasmid-mediated carbapenemase KPC-3 associated with OXA-9 and TEM-1. *J Antimicrob Chemother.* 2008; 61:455-57 <http://dx.doi.org/10.1093/jac/dkm455> PMID:18032422
 54. Cuzon G, Naas T, Demachy MC, Nordmann P. Nosocomial outbreak of *Klebsiella pneumoniae* harbouring bla(KPC-3) in France subsequent to a patient transfer from Italy. *Int J Antimicrob Agents.* 2012; 39:448-49. <http://dx.doi.org/10.1016/j.ijantimicag.2012.01.008> PMID:22421327
 55. Naas T, Cuzon G, Babics A, et al. Endoscopy-associated transmission of carbapenem-resistant *Klebsiella pneumoniae* producing KPC-2 beta-lactamase. *J Antimicrob Chemother.* 2010; 65:1305-06. <http://dx.doi.org/10.1093/jac/dkq117> PMID:20382724
 56. Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. *Euro Surveill.* 2015;20(45). <http://dx.doi.org/10.2807/1560-7917.ES.2015.20.45.30062> PMID:26675038
 57. Curiao T, Morosini MI, Ruiz-Garbjosa P, et al. Emergence of bla KPC-3-Tn4401a associated with a pKPN3/4-like plasmid within ST384 and ST388 *Klebsiella pneumoniae* clones in Spain. *J Antimicrob Chemother.* 2010; 65:1608-14. <http://dx.doi.org/10.1093/jac/dkq174> PMID:20513703
 58. Oteo J, Ortega A, Bartolomé R, et al. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem. *Antimicrob Agents Chemother.* 2015;59:3406-12. <http://dx.doi.org/10.1128/AAC.00086-15> PMID:25824224 PMCid:PMC4432182
 59. Palacios-Baena ZR, Oteo J, Conejo C, et al. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. *J Infect.* 2016;72:152-60. <http://dx.doi.org/10.1016/j.jinf.2015.10.008> PMID:26546855
 60. Bedenic B, Mazzariol A, Plecko V, Bošnjak Z, Barl P, Vraneš J, Cornaglia G. First report of KPC-producing *Klebsiella pneumoniae* in Croatia. *J Chemother.* 2012;24:237-9. <http://dx.doi.org/10.1179/1973947812Y.0000000017> PMID:23040691
 61. Jelic M, Butic I, Plecko V, et al. KPC-Producing *Klebsiella pneumoniae* Isolates in Croatia: A Nationwide Survey. *Microb Drug Resist.* 2015 Dec 28. <http://dx.doi.org/10.1089/mdr.2015.0150> PMID:26709956
 62. Kostyanev T, Tafaj S, Skenduli I, et al. First detection of KPC-3-producing *Klebsiella pneumoniae* in Albania. *New Microbes New Infect.* 2015 ;4:11-2.
 63. Bakour S, Sahli F, Touati A, Rolain JM. Emergence of KPC-producing *Klebsiella pneumoniae* ST512 isolated from cerebrospinal fluid of a child in Algeria. *New Microbes New Infect.* 2014;8:34-6.
 64. Metwally L, Gomaa N, Attallah M, Kamel N. High prevalence of *Klebsiella pneumoniae* carbapenemase-mediated resistance in *K. pneumoniae* isolates from Egypt. *East Mediterr Health J.* 2013;19:947-52. PMID:24673086
 65. Helal SF, El-Rachidi NG, AbdulRahman EM, Hassan DM. The presence of blaKPC-mediated resistance in Enterobacteriaceae in Cairo University hospitals in Egypt and its correlation with in vitro carbapenem susceptibility. *J Chemother* 2014;26:125-8. <http://dx.doi.org/10.1179/1973947813Y.0000000099> PMID:24592883
 66. Abdulall AK, El-Mahallawy HA, Abdo sa, Aly NK. Emergence of *Klebsiella pneumoniae* clinical isolates harboring *Klebsiella pneumoniae* carbapenemase and metallo-β-lactamase in two hospitals in Egypt. *New Egyptian Journal of Microbiology* 2014; 39:
 67. Walsh TR, Toleman MA, Poirel L, and Nordmann P. Metallo-β-lactamases: the quiet before the storm? *Clin Microbiol Rev* 2005;18:306-325.
 68. Vatopoulos A, High rates of metallo-β-lactamase-producing pneumoniae in Greece—a review of the current evidence. *Euro Surveillance*, vol. 13, no. 4, 2008. PMID:18445397
 69. Luzzaro F, Docquier JD, Colillon C, Endimiani A, Lombardi G, Amicosante G, Rossolini GM, Toniolo A. Emergence in *Klebsiella pneumoniae* and Enterobacter cloacae clinical isolates of the VIM-4 metallo-beta-lactamase encoded by a conjugative plasmid. *Antimicrob Agents Chemother.* 2004;48:648-50. <http://dx.doi.org/10.1128/AAC.48.2.648-650.2004> PMID:14742229 PMCid:PMC321512
 70. Aschbacher R, Doumith M, Livermore DM, Larcher C, Woodford N. Linkage of acquired quinolone resistance (qnrS1) and metallo-beta-lactamase (blaVIM-1) genes in multiple species of Enterobacteriaceae from Bolzano, Italy. *J Antimicrob Chemother.* 2008 ;61:515-23. <http://dx.doi.org/10.1093/jac/dkm508> PMID:18184647
 71. Aschbacher R, Pagani L, Doumith M, et al. Metallo-β-lactamases among Enterobacteriaceae from routine samples in an Italian tertiary-care hospital and long-term care facilities during 2008. *Clin Microbiol Infect.* 2011;17:181-9. <http://dx.doi.org/10.1111/j.1469-0691.2010.03225.x> PMID:20345467
 72. Cantón R, Akóva M, Carmeli Y, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. *Clin*

- Microbiol Infect. 2012 ;18:413-31. <http://dx.doi.org/10.1111/j.1469-0691.2012.03821.x> PMID:22507109
73. M.-F. Lartigue, L. Poirel, and P. Nordmann, "First detection of a carbapenem-hydrolyzing metalloenzyme in an Enterobacteriaceae isolate in France," *Antimicrob Agents Chemother*, 2004; 48:4929-4930. <http://dx.doi.org/10.1128/AAC.48.12.4929-4930.2004> PMID:15561885 PMCid:PMC529240
74. Barguigua A, El Otmani F, El Yaagoubi FL, Talmi M, Zerouali K, Timinouni M, First report of a Klebsiella pneumoniae strain coproducing NDM-1, VIM-1 and OXA-48 carbapenemases isolated in Morocco, *APMIS*, 2013;121:675-677. <http://dx.doi.org/10.1111/apm.12034> PMID:23278254
75. Poirel L, Abdelaziz MO, Bernabeu S, Nordmann P, Occurrence of OXA-48 and VIM-1 carbapenemase-producing Enterobacteriaceae in Egypt, *Intern J Antimicrob Agents*, 2013;41:90-91. <http://dx.doi.org/10.1016/j.ijantimicag.2012.08.015> PMID:23040010
76. Robin F, Aggoune-Khinache N, Delmas J, Naim M, Bonnet R, Novel VIM metallo- β -lactamase variant from clinical isolates of Enterobacteriaceae from Algeria, *Antimicrob Agents Chemother*, 2010;54:466-470. <http://dx.doi.org/10.1128/AAC.00017-09> PMID:19901092 PMCid:PMC2798476
77. Ktari S, Arlet G, Mnif B et al., "Emergence of multidrug-resistant Klebsiella pneumoniae isolates producing VIM-4 metallo- β -lactamase, CTX-M-15 extended-spectrum β -lactamase, and CMY-4 AmpC β -lactamase in a Tunisian University Hospital," *Antimicrob Agents Chemother*, 2006;50: 4198-4201. <http://dx.doi.org/10.1128/AAC.00663-06> PMID:17015633 PMCid:PMC1694011
78. Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-spectrum β -lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? *J Antimicrob Chemother*, 2011; 66:689-692. <http://dx.doi.org/10.1093/jac/dkq520> PMID:21393184
79. Kumarasamy KK, Toleman MA, Walsh TR et al., Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis*, 2010;10:597-602. [http://dx.doi.org/10.1016/S1473-3099\(10\)70143-2](http://dx.doi.org/10.1016/S1473-3099(10)70143-2)
80. Birgy A, Doit C, Mariani-Kurkdjian P et al., Early detection of colonization by VIM-1-producing Klebsiella pneumoniae and NDM-1-producing Escherichia coli in two children returning to France. *J Clin Microbiol*. 2011;49:3085-3087. <http://dx.doi.org/10.1128/JCM.00540-11> PMID:21653781 PMCid:PMC3147713
81. Giani T, Pini B, Arena F et al., Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey. *Eurosurveillance*, 2013;18:22.
82. Gil-Romero Y, Sanz-Rodriguez N, Almagro-Molto M, and Gomez-Garcés GM, New description of a NDM-1 carbapenemase producing Klebsiella pneumoniae carrier in Spain, *Enferm Infecc Microb Clin*, 2013;31: 418-419. <http://dx.doi.org/10.1016/j.eimc.2012.10.009> PMID:23218738
83. Oteo J, Domingo-García D, Fernández-Romero S et al., Abdominal abscess due to NDM-1-producing Klebsiella pneumoniae in Spain. *J Med Microbiol* 2012; 61:864-867. <http://dx.doi.org/10.1099/jmm.0.043190-0> PMID:22383442
84. Poirel L, Benouda A, Hays C, Nordmann P, Emergence of NDM-1-producing Klebsiella pneumoniae in Morocco. *J Antimicrob Chemother*. 2011;66: 2781-2783. <http://dx.doi.org/10.1093/jac/dkr384> PMID:21930570
85. Nasr AB, Decre D, Compain F, Genel N, Barguillil F, Arlet G. Emergence of NDM-1 in association with OXA-48 in Klebsiella pneumoniae from Tunisia. *Antimicrob Agents Chemother*, 2013; 57: 4089-4090. <http://dx.doi.org/10.1128/AAC.00536-13> PMID:23752514 PMCid:PMC3719753
86. Abdelaziz MO, Bonura C, Aleo A, Fasciana T, Mammina C. NDM-1 and OXA-163-producing Klebsiella pneumoniae isolates in Cairo, Egypt, 2012. *J Glob Antimicrob Resist* 2013;1:213-5. <http://dx.doi.org/10.1016/j.jgar.2013.06.003>
87. Poirel L, Ozdamar M, Ocampo-Sosa AA, Turkoglu S, Ozer UG, Nordmann P. NDM-1-producing Klebsiella pneumoniae now in Turkey. *Antimicrob Agents Chemother* 2012;56: 2784-2785. <http://dx.doi.org/10.1128/AAC.00150-12> PMID:22391536 PMCid:PMC3346671
88. Alp E, Percin D, Colakoglu S et al., Molecular characterization of carbapenem-resistant Klebsiella pneumoniae in a tertiary university hospital in Turkey. *J Hosp Infect*, 2013; 84:178-180. <http://dx.doi.org/10.1016/j.jhin.2013.03.002> PMID:23623803
89. Giakkoupi P, Tryfinopoulou K, Kontopidou F et al., Emergence of NDM-producing Klebsiella pneumoniae in Greece. *Diagn Microbiol Infect Dis* 2013; 77:382-384. <http://dx.doi.org/10.1016/j.diagmicrobio.2013.09.001> PMID:24135413
90. Psychogiou M, Tassios PT, Avlami A et al. Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. *J Antimicrob Chemother* 2008; 61: 59-63. <http://dx.doi.org/10.1093/jac/dkm443> PMID:17999975
91. Baroud M, Dandache I, Araj GF et al., Underlying mechanisms of carbapenem resistance in extended-spectrum β -lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases. *Intern J Antimicrob Agents*. 2013;41:75-79. <http://dx.doi.org/10.1016/j.ijantimicag.2012.08.010> PMID:23142087
92. Bialvaei AZ, Kafil HS, Leylabadlo HE, Asgharzadeh M, Aghazadeh M Dissemination of carbapenemases producing Gram negative bacteria in the Middle East. *Iran J Microbiol* 2015;7:226-246
93. Gefen-Halevi S, Hindiyeh MY, Ben-David D, Smollan G, Gal-Mor O, Azar R, et al. Isolation of genetically unrelated bla(NDM-1)-positive Providencia rettgeri strains in Israel. *J Clin Microbiol*.2013;51:1642-3. <http://dx.doi.org/10.1128/JCM.00381-13> PMID:23486709 PMCid:PMC3647926
94. Poirel L, H'eritier C, Tol'un V, Nordmann P, Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae," *Antimicrob Agents Chemother*, 2004;48:15-22 <http://dx.doi.org/10.1128/AAC.48.1.15-22.2004> PMID:14693513 PMCid:PMC310167
95. Carrer A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. *Antimicrob Agents Chemother* 2008;52:2950-4. <http://dx.doi.org/10.1128/AAC.01672-07> PMID:18519712 PMCid:PMC2493117
96. Aktas Z, Kayacan CB, Schneider I, Can B, Midilli K, Bauernfeind A. Carbapenem-hydrolyzing oxacillinase, OXA-48, persists in Klebsiella pneumoniae in Istanbul, Turkey. *Chemother* 2008;54:101-6. <http://dx.doi.org/10.1159/000118661> PMID:18303258
97. Cuzon G, Ouanich J, Gondret R, Naas T, Nordmann P, Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. *Antimicrob Agents Chemother*. 2011;55: 2420-2423. <http://dx.doi.org/10.1128/AAC.01452-10> PMID:21343451 PMCid:PMC3088266
98. Potron A, Poirel L, Rondinaud E, Nordmann P, Intercontinental spread of OXA-48 beta-lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011. *Eurosurveillance*, 2013; 18:31. <http://dx.doi.org/10.2807/1560-7917.ES2013.18.31.20549>
99. Benouda A, Touzani O, Khairallah MT, Araj GF, Matar GM, First detection of oxacillinase-mediated resistance to carbapenems in Klebsiella pneumoniae from Morocco. *Ann Trop Med Parasitol* 2010;104:327-330. <http://dx.doi.org/10.1179/136485910X12743554760108> PMID:20659393
100. Voulgari E, Zarkotou O, Ranellou K et al., Outbreak of OXA-48 carbapenemase-producing Klebsiella pneumoniae in Greece involving an ST11 clone. *J Antimicrob Chemother*. 2013; 68:84-88. <http://dx.doi.org/10.1093/jac/dks356> PMID:22945916
101. Adler A, Shklyar M, Schwaber MJ et al., Introduction of OXA-48-producing enterobacteriaceae to Israeli hospitals by medical tourism. *J Antimicrob Chemother*. 2011; 66:2763-2766. <http://dx.doi.org/10.1093/jac/dkr382> PMID:22191089
102. Matar GM, Dandache I, Carr'er A et al., Spread of OXA-48-mediated resistance to carbapenems in Lebanese Klebsiella pneumoniae and Escherichia coli that produce extended spectrum β -lactamase. *Ann Tropic Med Parasitol* 2010;104:271-274. <http://dx.doi.org/10.1179/136485910X12647085215651> PMID:20507701
103. Matar GM, Cuzon G, Araj GF et al., "Oxacillinase mediated resistance to carbapenems in Klebsiella pneumoniae from Lebanon," *Clin Microbiol Infect* 2008;14:887-888. <http://dx.doi.org/10.1111/j.1469-0691.2008.02059.x> PMID:18844693
104. Pir's M, Andlovic A, Cerar T et al., A case of OXA-48 carbapenemase-producing Klebsiella pneumoniae in a patient

- transferred to Slovenia from Libya, November 2011. *Euro Surveill*, 2011;16:50.
105. Oteo J, Hern'andez JM, Espasa M et al., Emergence of OXA-48-producing *Klebsiella pneumoniae* and the novel carbapenemases OXA-244 and OXA-245 in Spain. *J Antimicrob Chemother*.2013;68:317-321. <http://dx.doi.org/10.1093/jac/dks383> PMID:23034714
 106. Ktari S, Mnif B, Louati F et al., Spread of *Klebsiella pneumoniae* isolates producing OXA-48 β -lactamase in a Tunisian university hospital. *J Antimicrob Chemother* 2011; 66: 1644-1646. <http://dx.doi.org/10.1093/jac/dkr181> PMID:21565807
 107. Hays C, Benouda A, Poirer L, Elouennass M, and Nordmann P, Nosocomial occurrence of OXA-48-producing enterobacterial isolates in a Moroccan hospital, *Intern J Antimicrob Ag*, 2012;39:545-547. <http://dx.doi.org/10.1016/j.ijantimicag.2012.03.002> PMID:22521525
 108. Barguigua A, ElOtmami E, Talmi M, Zerouali K, and Timinouni M Emergence of carbapenem-resistant Enterobacteriaceae isolates in the Moroccan community. *Diagn Microbiol Infect Dis*, 2012;73: 290-291. <http://dx.doi.org/10.1016/j.diagmicrobio.2012.03.011> PMID:22521054
 109. Kraiem AG, Zorgani A, Elahmer O, Hammami A, Chaaben BM, Ghenghesh KS. New Delhi metallo- β -lactamase and OXA-48 carbapenemases in Gram-negative bacilli isolates in Libya. *Libyan J Med*. 2015;10:29206. <http://dx.doi.org/10.3402/ljm.v10.29206> PMID:26294290 PMCID:PMC4543448
 110. Lafeuille E, Decré D, Mahjoub-Messai F, Bidet P, Arlet G, Bingen E. OXA-48 carbapenemase-producing *Klebsiella pneumoniae* isolated from Libyan patients. *Microb Drug Resist*. 2013 ;19:491-7. <http://dx.doi.org/10.1089/mdr.2012.0219> PMID:23808959
 111. Kocsis E, Savio C, Piccoli M, Cornaglia G, Mazzariol A. *Klebsiella pneumoniae* harbouring OXA-48 carbapenemase in a Libyan refugee in Italy. *Clin Microbiol Infect*. 2013;19:E409-11. Pirš M, Andlovic A, Cerar T, Žohar-Čretnik T, Kobola L, Kolman J, Freljih T, Prešern-Štrukelj M, Ružić-Sabljić E, Seme K. A case of OXA-48 carbapenemase-producing *Klebsiella pneumoniae* in a patient transferred to Slovenia from Libya, November 2011. *Euro Surveill*. 2011;16:20042
 112. Hammerum AM, Larsen AR, Hansen F, Justesen US, Friis-Møller A, Lemming LE, Fursted K, Littauer P, Schønning K, Gahrn-Hansen B, Ellermann-Eriksen S, Kristensen B. Patients transferred from Libya to Denmark carried OXA-48-producing *Klebsiella pneumoniae*, NDM-1-producing *Acinetobacter baumannii* and methicillin-resistant *Staphylococcus aureus*. *Int J Antimicrob Agents*. 2012 ;40:191-2. <http://dx.doi.org/10.1016/j.ijantimicag.2012.05.003> PMID:22743013
 113. Pirš M, Andlovic A, Cerar T, Žohar-Čretnik T, Kobola L, Kolman J, Freljih T, Prešern-Štrukelj M, Ružić-Sabljić E, Seme K. A case of OXA-48 carbapenemase-producing *Klebsiella pneumoniae* in a patient transferred to Slovenia from Libya, November 2011. *Euro Surveill*. 2011;16:20042